These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. Kepenekian V, Elias D, Passot G, Mery E, Goere D, Delroeux D, Quenet F, Ferron G, Pezet D, Guilloit JM, Meeus P, Pocard M, Bereder JM, Abboud K, Arvieux C, Brigand C, Marchal F, Classe JM, Lorimier G, De Chaisemartin C, Guyon F, Mariani P, Ortega-Deballon P, Isaac S, Maurice C, Gilly FN, Glehen O, French Network for Rare Peritoneal Malignancies (RENAPE). Eur J Cancer; 2016 Sep; 65():69-79. PubMed ID: 27472649 [Abstract] [Full Text] [Related]
3. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ihemelandu C, Bijelic L, Sugarbaker PH. Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250 [Abstract] [Full Text] [Related]
4. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma. Huang Y, Alzahrani NA, Liauw W, Morris DL. Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745 [Abstract] [Full Text] [Related]
5. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center. Aydin N, Sardi A, Milovanov V, Nieroda C, Sittig M, Nunez MF, Jimenez W, Gushchin V. Am Surg; 2015 Dec; 81(12):1253-9. PubMed ID: 26736164 [Abstract] [Full Text] [Related]
6. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC. Robella M, Vaira M, Mellano A, Marsanic P, Cinquegrana A, Borsano A, Barbera M, Caneparo A, Siatis D, Sottile A, De Simone M. Minerva Chir; 2014 Feb; 69(1):9-15. PubMed ID: 24675242 [Abstract] [Full Text] [Related]
7. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Acs M, Gerken M, Gajic I, Mayr M, Zustin J, Piso P. Langenbecks Arch Surg; 2022 Nov; 407(7):3057-3067. PubMed ID: 35732846 [Abstract] [Full Text] [Related]
10. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial. de Boer NL, van Kooten JP, Burger JWA, Verhoef C, Aerts JGJV, Madsen EVE. BMJ Open; 2019 May 14; 9(5):e026779. PubMed ID: 31092657 [Abstract] [Full Text] [Related]
12. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience. Iversen LH, Rasmussen PC, Hagemann-Madsen R, Laurberg S. Colorectal Dis; 2013 Jul 14; 15(7):e365-72. PubMed ID: 23458368 [Abstract] [Full Text] [Related]
13. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study. Hommell-Fontaine J, Isaac S, Passot G, Decullier E, Traverse-Glehen A, Cotte E, You B, Mohamed F, Gilly FN, Glehen O, Berger F. Ann Surg Oncol; 2013 Nov 14; 20(12):3892-8. PubMed ID: 23800898 [Abstract] [Full Text] [Related]
14. Multicystic and diffuse malignant peritoneal mesothelioma in children. Vermersch S, Arnaud A, Orbach D, Andre N, Berger C, Kepenekian V, Brigand C, Fresneau B, Poli-Merol ML, Habougit C, Varlet F, Scalabre A. Pediatr Blood Cancer; 2020 Jun 14; 67(6):e28286. PubMed ID: 32277799 [Abstract] [Full Text] [Related]
15. [Diffuse malignant peritoneal mesothelioma (DMPM) - a rare diagnosis]. Habbel VSA, Mahler EA, Feyerabend B, Oldhafer KJ, Lipp MJ. Z Gastroenterol; 2020 Feb 14; 58(2):146-151. PubMed ID: 32050285 [Abstract] [Full Text] [Related]
16. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma. Tan GH, Cheung M, Chanyaputhipong J, Soo KC, Teo MC. Ann Acad Med Singap; 2013 Jun 14; 42(6):291-6. PubMed ID: 23842770 [Abstract] [Full Text] [Related]
17. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. J Clin Oncol; 2009 Dec 20; 27(36):6237-42. PubMed ID: 19917862 [Abstract] [Full Text] [Related]
18. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Tan GHC, Chia CS, Tan SH, Soo KC, Teo MCC. Int J Clin Oncol; 2018 Oct 20; 23(5):989-998. PubMed ID: 29869757 [Abstract] [Full Text] [Related]
19. Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China. Su YD, Yang ZR, Li XB, Yu Y, Du XM, Li Y. Int J Hyperthermia; 2022 Oct 20; 39(1):706-712. PubMed ID: 35485308 [Abstract] [Full Text] [Related]
20. Advances in malignant peritoneal mesothelioma. Cao S, Jin S, Cao J, Shen J, Hu J, Che D, Pan B, Zhang J, He X, Ding D, Gu F, Yu Y. Int J Colorectal Dis; 2015 Jan 20; 30(1):1-10. PubMed ID: 25331029 [Abstract] [Full Text] [Related] Page: [Next] [New Search]